SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children
SeaStar Medical (NASDAQ: ICU) announced positive preliminary results from the SAVE Surveillance Registry for its QUELIMMUNE therapy in treating pediatric Acute Kidney Injury (AKI). The data, presented at the 5th International Symposium on AKI in Children, showed impressive outcomes from the first 21 pediatric patients with AKI and sepsis requiring Renal Replacement Therapy (RRT).
Key results include zero device-related adverse events, a 76% survival rate at Days 28 and 60, and 71% survival at Day 90. Among ECMO patients, the therapy demonstrated a 60% survival rate at Day 90. For survivors without prior ESRD or recent kidney transplant, 82% were dialysis-free at Day 90.
The SAVE Registry will continue collecting Real-World Evidence for up to 300 patients to support broader adoption and inform payer discussions.SeaStar Medical (NASDAQ: ICU) ha annunciato risultati preliminari positivi dal Registro di Sorveglianza SAVE per la sua terapia QUELIMMUNE nel trattamento della lesione renale acuta pediatrica (AKI). I dati, presentati al 5th International Symposium on AKI in Children, hanno mostrato esiti incoraggianti nei primi 21 pazienti pediatrici con AKI e sepsi che richiedevano la Terapia di Sostituzione Renale (RRT).
Tra i risultati chiave: assenza di eventi avversi legati al dispositivo, una tasso di sopravvivenza del 76% al Giorno 28 e 60, e sopravvivenza del 71% al Giorno 90. Tra i pazienti ECMO, la terapia ha mostrato una sopravvivenza del 60% al Giorno 90. Per i sopravvissuti senza ESRD pregressa o trapianto renale recente, l’82% era senza dialisi al Giorno 90.
Il Registro SAVE continuerà a raccogliere evidenze nel mondo reale fino a 300 pazienti per supportare una più ampia adozione e informare le discussioni con i payer.
SeaStar Medical (NASDAQ: ICU) anunció resultados preliminares positivos del Registro de Vigilancia SAVE para su terapia QUELIMMUNE en el tratamiento de la Lesión Renal Aguda pediátrica (AKI). Los datos, presentados en el 5º Simposio Internacional sobre AKI en Niños, mostraron resultados impresionantes en los primeros 21 pacientes pediátricos con AKI y sepsis que requerían Terapia de Reemplazo Renal (RRT).
Entre los resultados clave se incluyen cero eventos adversos relacionados con el dispositivo, una tasa de supervivencia del 76% en los Días 28 y 60, y 71% de supervivencia en el Día 90. Entre los pacientes con ECMO, la terapia demostró una supervivencia del 60% en el Día 90. Para los supervivientes sin ESRD previa o trasplante renal reciente, el 82% estaban libres de diálisis en el Día 90.
El Registro SAVE continuará recopilando Evidencia del Mundo Real hasta 300 pacientes para apoyar una adopción más amplia e informar las discusiones con los pagadores.
SeaStar Medical (NASDAQ: ICU)가 소아 신부전 AKI 치료를 위한 QUELIMMUNE 치료에 대한 SAVE Surveillance Registry의 긍정적 예비 결과를 발표했습니다. 5번째 국제 소아 AKI 심포지엄에서 발표된 데이터는 Renal Replacement Therapy(RRT)가 필요한 AKI 및 패혈증을 동반한 최초의 21명의 소아 환자에서 인상적인 결과를 보였습니다.
핵심 결과로는 기기 관련 부작용 없음, 28일 및 60일에 76% 생존율, 90일에 71% 생존율이 포함됩니다. ECMO 환자 중 치료는 90일째 60% 생존율을 보였습니다. 이전 ESRD나 최근 신장 이식이 없는 생존자 중 82%가 90일째 투석 없이 남아 있었습니다.
SAVE Registry는 최대 300명까지 실세계 증거를 계속 수집하여 더 넓은 채택을 뒷받침하고 지불자와의 논의에 정보를 제공할 예정입니다.
SeaStar Medical (NASDAQ: ICU) a annoncé des résultats préliminaires positifs du registre de surveillance SAVE pour sa thérapie QUELIMMUNE dans le traitement de l’AKI pédiatrique (lésion rénale aiguë). Les données, présentées au 5ème Symposium International sur l’AKI chez l’Enfant, montrent des résultats impressionnants chez les 21 premiers patients pédiatriques atteints d’AKI et de sepsis nécessitant une THR (thérapie de remplacement rénal).
Les résultats clés incluent Aucun événement indésirable lié au dispositif, un taux de survie de 76% au Jour 28 et 60, et 71% de survie au Jour 90. Chez les patients sous ECMO, la thérapie a démontré une survie de 60% au Jour 90. Pour les survivants sans ESRD antérieure ou transplantation rénale récente, 82% étaient dialysis-free au Jour 90.
Le registre SAVE continuera de collecter des preuves du monde réel jusqu’à 300 patients pour soutenir une adoption plus large et éclairer les discussions avec les payeurs.
SeaStar Medical (NASDAQ: ICU) gab positive vorläufige Ergebnisse aus dem SAVE Surveillance Registry für ihre QUELIMMUNE-Therapie bei der Behandlung von pädiatrischer AKI (Acute Kidney Injury). Die Daten, vorgestellt beim 5. Internationalen Symposium über AKI bei Kindern, zeigten beeindruckende Resultate bei den ersten 21 pädiatrischen Patienten mit AKI und Sepsis, die eine Renale Replacement Therapy (RRT) benötigten.
Zu den Schlüsselresultaten gehören keine gerätebedingten unerwünschten Ereignisse, eine Überlebensrate von 76% an Tag 28 und 60, sowie 71% Überleben an Tag 90. Unter ECMO-Patienten zeigte die Therapie eine Überlebensrate von 60% an Tag 90. Bei Überlebenden ohne vorherige ESRD oder kürzlichen Nierentransplantationen waren 82% an Tag 90 dialysefrei.
Das SAVE-Register wird weiterhin Real-World-Evidence bis zu 300 Patienten sammeln, um eine breitere Einführung zu unterstützen und Diskussionen mit Kostenträgern zu informieren.
SeaStar Medical (NASDAQ: ICU) أعلنت عن نتائج أولية إيجابية من سجل المراقبة SAVE لعلاجها QUELIMMUNE في علاج الإصابة الكلوية الحادة عند الأطفال (AKI). البيانات، التي عُرضت في المؤتمر الدولي الخامس ل AKI عند الأطفال، أظهرت نتائج مميزة لأول 21 مريضاً أطفالاً مصابين بـ AKI و تعفن الدم الذي يتطلب علاج الاستبدال الكلوي (RRT).
تشمل النتائج الرئيسية عدم وجود أحداث سلبية مرتبطة بالجهاز، و<نسبة بقاء 76% في اليوم 28 و60، و< b>71% بقـاء في اليوم 90. من بين مرضى ECMO، أظهرت العلاج نسبة بقاء قدرها 60% في اليوم 90. بالنسبة للموجودين أحياء بدون ESRD مسبقاً أو زراعة كلية حديثة، كان 82% بدون غسيل كلوي في اليوم 90.
سيستمر سجل SAVE في جمع أدلة العالم الحقيقي حتى 300 مريض لدعم اعتماد أوسع وإبلاغ المناقشات مع الجهات الدافعة.
SeaStar Medical (NASDAQ: ICU) 宣布其< b>QUELIMMUNE疗法在治疗儿科急性肾损伤（AKI）方面的SAVE监测注册的积极初步结果。数据在第5届国际儿童AKI研讨会上公布，显示在前21名需肾脏替代治疗（RRT）的AKI合并败血症的儿科患者中的令人印象深刻的结局。
关键结果包括< b>与设备相关的不良事件为零，在28天和60天的生存率为< b>76%，在第90天为< b>71%。在ECMO患者中，该治疗在第90天显示了< b>60%的生存率。对于未有长期 ESRD 或近期肾移植的幸存者，90天时< b>82%无透析.
SAVE注册将继续收集真实世界证据，至多300名患者，以支持更广泛的采用并为支付方讨论提供信息。
- Zero device-related adverse events or infections reported
- 76% survival rate at Day 28 and Day 60, with 71% survival at Day 90
- 60% survival rate for ECMO patients at Day 90
- 82% of surviving patients were dialysis-free at Day 90
- Potential 50% reduction in loss of life compared to historical data
- Limited sample size of only 21 patients in initial results
- Full 300-patient data still pending for comprehensive validation
Insights
SeaStar's QUELIMMUNE therapy shows promising early safety and efficacy data in pediatric AKI patients, potentially reducing mortality by 50%.
SeaStar Medical has shared encouraging preliminary data from its SAVE Surveillance Registry for the QUELIMMUNE therapy (Selective Cytopheretic Device for Pediatrics) in treating critically ill pediatric patients with Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). The data revealed zero device-related adverse events and demonstrated impressive survival rates of
These survival outcomes are particularly significant as they appear on track to validate or exceed a
The data from subgroups is equally promising. Among the most critically ill patients – those requiring both QUELIMMUNE therapy and extracorporeal membrane oxygenation (ECMO) –
The company is collecting real-world evidence (RWE) for up to 300 patients treated with QUELIMMUNE. These initial positive results could accelerate clinical adoption at major children's hospitals, strengthen reimbursement discussions with payers, and potentially boost enrollment in the company's adult NEUTRALIZE-AKI pivotal trial, expanding the technology's applications beyond pediatrics to a much larger market.
Data show results consistent with clinical trial experience
A high level of safety – no device-related adverse events
Strong survival data extending to 90 days
DENVER, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveillance Registry presented on Saturday, September 27, 2025, at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Registry presentation highlighted the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT).
Data from the first 21 pediatric patients with AKI and sepsis requiring RRT showed zero device-related adverse events or infections and no reports of immunosuppressive effects by the device. In addition, outcomes analyses show a
Additional analyses included survival of patients requiring extracorporeal membrane oxygenation (ECMO) and independence from renal replacement therapy (RRT) for pediatric patients without a history of end-stage renal disease (ESRD) or a recent kidney transplant. The evaluation of five patients concomitantly treated with the QUELIMMUNE therapy and ECMO showed a
“As a clinician and nephrologist, I have watched for more than two decades the damage to organ function and loss of life due to the hyperactive immune response in children and young adults who deserve better treatments to mitigate this condition,” stated Stuart Goldstein, MD, of Cincinnati Children’s. “These results and my own clinical experience provide encouraging evidence to show early benefit of SCD-PED therapy in critically ill patients with AKI requiring RRT.”
“We continue to see consistent, reproducible results from the use of the QUELIMMUNE SCD-PED therapy in clinical practice,” stated Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “We are especially pleased that the QUELIMMUNE therapy gave the most critically ill children a fighting chance. I am certain most would not be alive today without this therapy.”
The SAVE Surveillance Registry is a Real-World Evidence (RWE) surveillance program that is designed to confirm safety and efficacy of the QUELIMMUNE therapy. Medical institutions employing the QUELIMMUNE therapy will continue to collect RWE for up to the first 300 patients treated with QUELIMMUNE. Specific outcomes data will include 90-day survival and dialysis dependency along with safety data with plans to compare to an existing control group of similar illness severity. SeaStar Medical believes that initial results from the SAVE Surveillance Registry will support broader adoption of the QUELIMMUNE therapy, inform payer discussions, and complement the company’s ongoing effort to recruit patients into its adult NEUTRALIZE-AKI pivotal trial.
The QUELIMMUNE therapy has been adopted by nationally recognized children’s medical centers in the United States. The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and has broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.
About Acute Kidney Injury (AKI) and Hyperinflammation
AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as sepsis, severe trauma, surgery and COVID-19. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.
About QUELIMMUNE
The QUELIMMUNE™ therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are on antibiotics and being treated in the ICU with Renal Replacement Therapy (RRT). It was approved in February 2024 under a Humanitarian Device Exemption application that requires medical institutions to also participate in the SAVE Surveillance Registry and complete Institutional Review Board approvals prior to adoption and use of the QUELIMMUNE therapy. This prolongs the adoption timeline by medical institutions, but provides important data on the use of QUELIMMUNE in the “real-world” setting.
Data from two clinical studies of the QUELIMMUNE therapy, published in Kidney Medicine, showed a
In January 2025, SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its significant contribution to improving the lives of pediatric patients with AKI based on the approval and introduction of the QUELIMMUNE therapy.
About the SeaStar Medical Selective Cytopheretic Device Therapy
The Selective Cytopheretic Device (SCD) therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy has broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing CRRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future RRT, including dialysis, and prevent loss of life.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the anticipated adoption our products; anticipated cost savings for patients, healthcare providers, and the healthcare system more generally from the adoption of the SCD therapy; the reduction in loss of life; the potential results of the Save Surveillance Registry study; t; the ability of SeaStar Medical to gain market share and generate sales with respect to the total addressable market for adult SCD applications; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
IR@SEASTARMED.COM
FAQ
What are the survival rates for SeaStar Medical's QUELIMMUNE therapy in pediatric AKI patients?
How effective is QUELIMMUNE therapy for ECMO patients with AKI?
What percentage of ICU's QUELIMMUNE patients become dialysis-free?
Are there any safety concerns with SeaStar Medical's QUELIMMUNE device?
How many patients will be included in SeaStar Medical's SAVE Registry study?
